BioSpace News Archive

Drug Development

Kodiak Breathes New Life into Failed Eye Drug with Phase III Victory

Although Kodiak Sciences initially scrapped its development of tarcocimab tedromer after late-stage failures, new data has convinced the company to give the eye drug another shot.

November 6, 2023
·
2 min read
·
Tyler Patchen
Drug Development

Travere Touts Phase III Kidney Disease Data for Filspari After Trial Failures

Following two late-stage failures, Travere Therapeutics has unveiled the results of two Phase III studies, attempting to regain Filspari’s footing in IgA nephropathy and focal segmental glomerulosclerosis.

November 6, 2023
·
2 min read
·
Tristan Manalac
Business

Pfizer’s $3.5B Cost-Cutting Program Claims 200 Jobs at Michigan Site

Seeking to weather declining sales from its COVID-19 business in the third quarter, Pfizer is laying off approximately 200 employees at its manufacturing facility in Kalamazoo, Michigan.

November 6, 2023
·
2 min read
·
Tristan Manalac
Business

BMS Pays $100M Upfront for ADC from Korean Biotech Orum Therapeutics

After its deal with Tubulis in April 2023, Bristol Myers Squibb is continuing its antibody-drug conjugate buying spree by acquiring an asset from South Korea’s Orum Therapeutics.

November 6, 2023
·
2 min read
·
Tyler Patchen
Biotech Beach

Nexcella Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 63 Relapsed/Refractory Multiple Myeloma Patients

Nexcella, Inc. today announced that updated NXC-201 relapsed/refractory multiple myeloma clinical data has been selected for presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

November 6, 2023
·
7 min read
BioMidwest

Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 Trial

Sermonix Pharmaceuticals Inc., announced that a case report detailing a durable complete remission during its Phase 2 ELAINE-1 study was published in JCO Precision Oncology.

November 6, 2023
·
6 min read
Drug Development

SELLAS Life Sciences Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in WT1+ Platinum-Resistant Advanced Ovarian Cancer at the IGCS 2023 Annual Global Meeting

SELLAS Life Sciences Group, Inc. announced final clinical and immunobiological data from the Phase 1/2 clinical trial of galinpepimut-S in combination with pembrolizumab in Wilms’ tumor-1 -positive platinum-resistant ovarian cancer.

November 6, 2023
·
9 min read
Biotech Beach

EpicentRx To Present Nibrozetone (RRx-001) Data on Parkinson’s Disease and ALS/MND at Neuroscience 2023

EpicentRx, Inc. (“EpicentRx”) has been selected for oral and poster presentations at the prestigious Society for Neuroscience’s Neuroscience 2023, an international conference taking place in Washington, D.C. from Saturday, November 11 to Wednesday, November 15, 2023.

November 6, 2023
·
3 min read
Biotech Beach

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma, Inc. today announced that additional NXC-201 clinical data in relapsed/refractory AL Amyloidosis has been selected for oral presentation at the upcoming 65th American Society of Hematology (ASH) Annual Meeting to be held in San Diego, California, December 9-12, 2023.

November 6, 2023
·
8 min read
Drug Development

GT Biopharma Presented Positive Preclinical Data for GTB-5550, a Novel TriKE® Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

GT Biopharma, Inc. today announced positive preclinical data in highlighting GTB-5550’s potential in prostate cancer.

November 6, 2023
·
4 min read